Foghorn therapeutics strengthens financial leadership with appointment of kristian humer as chief financial officer

Cambridge, mass., april 16, 2024 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that kristian humer will join the company as chief financial officer (cfo) on april 16, 2024. mr. humer joins foghorn with over 14 years of diversified financial strategy and business development experience in the life science industry and more than 20 years of experience in the financial industry.
FHTX Ratings Summary
FHTX Quant Ranking